Evvy

Score breakdown

Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.

Evvy focuses on vaginal health, including recurrent symptoms and questions about the vaginal microbiome. Tiny Health’s vaginal test is an alternative for the overlapping at-home testing job. Evvy does not replace Tiny Health’s infant or adult gut tests, and those different specimen types should not be treated as competing services.

The published test price makes Evvy a relatively accessible self-pay testing purchase, with repeat testing, expanded panels, and treatment increasing the total. The more important difference is what follows a result: Evvy offers clinician review and prescriptions when appropriate, while lifestyle and supplement recommendations are a separate kind of support.

• Clinical usefulness and evidence (7.0): Testing and published research offer detailed information, but microbiome findings require clinical interpretation.
• Testing and follow-up options (8.0): Sequencing, clinician review, and eligible prescription care provide a connected test-to-care service.
• Collection and care access (7.8): At-home swabbing is accessible, while treatment eligibility and symptoms can require other care.
• Pricing clarity (8.1): Test and subscription prices are public, with prescriptions and optional products adding separate costs.

What the Test and Care Path Provide

A customer collects a vaginal swab at home and sends it to the laboratory. Evvy uses metagenomic sequencing to report bacteria and fungi, then supplies clinician-reviewed results and a personalized plan. Its current offer includes an optional expanded PCR panel and access to a health coach.

Prescription treatment is determined by an affiliated clinician and eligibility. A probiotic, wellness recommendation, or AI-generated explanation is not a prescription or a substitute for clinical judgment. The service’s usefulness depends on connecting the report to symptoms, medical history, and a suitable treatment decision.

Interpreting Results Without Overreading Them

Evvy’s research and care model aim to connect microbiome patterns with symptoms and outcomes. A detailed report can help structure a clinical conversation, especially after recurrent symptoms. It does not mean every detected organism is causing disease or that every person with the same microbial pattern needs the same intervention.

An opened Reddit account described receiving a BV interpretation that conflicted with an in-person assessment. That is one patient’s account, not a measured error rate. It illustrates why a result that conflicts with symptoms or another clinician’s assessment deserves review before treatment changes. Evvy’s stated clinical pathway and a person’s usual healthcare professional can both be relevant to that discussion.

Product and service details: evvy.com, evvy.com.

Company scale

HIR estimates Evvy annual revenue below $100 million, based on its disclosed cumulative footprint of more than 100,000 patients, published test prices, and financing-stage business. Its September 2026 $40 million Series B is funding, not revenue. Scale source

What People Say

What people like

"For the first time since developing symptoms, I felt heard, understood, and cared for. I could cry from happiness!"

Evvy

"The level of detail in test results is unlike anything I could ever access through my doctor’s office"

Evvy

What people don't like

"I brought the results to my OB, who examined me and confirmed I did not have BV."

Reddit

The comparison below applies only to vaginal microbiome testing. Tiny Health’s overall score also reflects its broader family and gut-testing business; it is not a separate score for the vaginal test.

Competitor landscape

Pricing

Leadership

• Priyanka JainCo-founder and CEO

Recent news

• September 2026: Evvy announced a $40 million Series B led by Catalio Capital Management to expand its women’s-health testing, care, and research work.